He wants to cut carbon emissions and lower fuel costs. Will this be good for GEVO? tia.
after the market close on friday. This is very bullish for ng. Below is from hiddenvalueinvestor on Seeking Alpha.
The EIA has revised its estimate for first quarter natural gas production down by a whopping 2 Bcf/d from 74 Bcf/d to 72 Bcf/d.
The EIA has revised first quarter natural gas consumption up by .7 Bcf/d from 96.3 Bcf/d to 97 Bcf/d.
The massive revision to production and consumption leads one to question if the EIA storage model is correct and will it be revised to show less natural gas in storage?
1% a year for the next 6 years. I started shorting DGAZ today. Let the decay work in my favor.
Natural gas production in the Marcellus shale, which has grown over the past decade from near zero to ~20% of U.S. output, may decline for the first time if prices in the basin remain low for much longer, the U.S. Energy Information Administration says.
"Relatively low gas prices, combined with low oil prices, have slowed drilling in the Marcellus so production from new wells is only offsetting the decline in old wells," EIA says, expecting Marcellus output to remain flat through 2018 before declining ~1%/year during 2019-25.
Recent data indicates a potential slowdown: The number of rigs in the area has dwindled to its lowest since 2011, and drillers including Chesapeake Energy (NYSE:CHK) and Cabot Oil & Gas (NYSE:COG) have temporarily shut in some production due to weak regional prices.
An inability to move all the gas out of the Marcellus region has depressed prices there compared with the Gulf coast benchmark, the Henry Hub in Louisiana, making it less attractive for local producers to drill more.
Sales are collapsing and the losses are huge. GEVO will need to raise more cash 3 months from in order to survive. Gruber needs to sign a licensing deal in that time frame too so he isn't trying to raise cash at a low price. Only time will tell how this plays out.
Item 8.01. Other Events.
On April 14, 2015, Coherus BioSciences, Inc. (“Coherus”) obtained positive results of a repeat Phase 1 pharmacokinetic (PK) bioequivalence study for CHS-0214, its etanercept (Enbrel®) biosimilar candidate. This study was initiated due to the change in the manufacturing location from the United States to the European Union of its CHS-0214 biosimilar candidate, and compared the E.U. produced CHS-0214 to a lot of Enbrel manufactured in Europe. The design of this trial was a single-dose, cross-over study that enrolled 53 healthy volunteers, of which 44 completed the study. The study met all bioequivalence criteria, as the 90% confidence intervals of the ratio for all parameters (maximum serum concentration (Cmax), area under the time-concentration curve from first to last time point measured (AUC0-t), and area under the time-concentration curve from first time point to infinity (AUC0-inf)) fall fully within the bioequivalence boundaries of 80-125%.
Sentiment: Strong Buy
give buy rec's. Selling to pay taxes will end after tomorrow too.
Sentiment: Strong Buy